NO20042711L - Fremgangsmate for a behandle bakterielle infeksjoner ved anvendelse av gemifloksasin eller et salt derav et betalaktamantibiotikum - Google Patents

Fremgangsmate for a behandle bakterielle infeksjoner ved anvendelse av gemifloksasin eller et salt derav et betalaktamantibiotikum

Info

Publication number
NO20042711L
NO20042711L NO20042711A NO20042711A NO20042711L NO 20042711 L NO20042711 L NO 20042711L NO 20042711 A NO20042711 A NO 20042711A NO 20042711 A NO20042711 A NO 20042711A NO 20042711 L NO20042711 L NO 20042711L
Authority
NO
Norway
Prior art keywords
gemifloxacin
beta
salt
bacterial infections
lactam antibiotic
Prior art date
Application number
NO20042711A
Other languages
English (en)
Other versions
NO333196B1 (no
Inventor
Nancy Niconovich
Stephen Rittenhouse
Lynn Mccloskey
Kyong-Sook Pack
Mu-Yong Kim
Ha-Sik Youn
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of NO20042711L publication Critical patent/NO20042711L/no
Publication of NO333196B1 publication Critical patent/NO333196B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår en fremgangsmåte for behandling av bakterielle infeksjoner hvor fremgangsmåten omfatter separat, samtidig eller etterfølgende administrering av en effektiv mengde av gemifloksasin eller et salt derav og et P-laktamantibiotikum til en pasient med behov for slik behandling.
NO20042711A 2001-11-30 2004-06-28 Anvendelse av gemifloksasin eller et salt derav, og et betalaktamantibiotikum for fremstilling av et medikament til behandling av bakterielle infeksjoner, samt sett omfattende gemifloksasin eller et salt derav og en betalaktamantibiotikaformulering NO333196B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33449501P 2001-11-30 2001-11-30
PCT/KR2002/002248 WO2003045390A1 (en) 2001-11-30 2002-11-29 A METHOD OF TREATING BACTERIAL INFECTIONS USING GEMIFLOXACIN OR A SALT THEREOF AND A β -LACTAM ANTIBIOTIC

Publications (2)

Publication Number Publication Date
NO20042711L true NO20042711L (no) 2004-06-30
NO333196B1 NO333196B1 (no) 2013-04-02

Family

ID=23307473

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042711A NO333196B1 (no) 2001-11-30 2004-06-28 Anvendelse av gemifloksasin eller et salt derav, og et betalaktamantibiotikum for fremstilling av et medikament til behandling av bakterielle infeksjoner, samt sett omfattende gemifloksasin eller et salt derav og en betalaktamantibiotikaformulering

Country Status (13)

Country Link
US (1) US7169792B2 (no)
EP (1) EP1458391B1 (no)
AT (1) ATE372119T1 (no)
AU (1) AU2002360218A1 (no)
CA (1) CA2468036C (no)
CY (1) CY1107038T1 (no)
DE (1) DE60222298T2 (no)
DK (1) DK1458391T3 (no)
ES (1) ES2292844T3 (no)
MX (1) MXPA04005179A (no)
NO (1) NO333196B1 (no)
PT (1) PT1458391E (no)
WO (1) WO2003045390A1 (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20080289A1 (it) * 2008-02-22 2009-08-23 S I F I Societa Industria Farmaceutica Italia Composizioni di gemifloxacina con elevata efficacia su patologie oculari
EP2143422A1 (en) * 2008-07-11 2010-01-13 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic compositions containing gemifloxacin for the treatment of ocular infections
EP2536408A1 (en) * 2010-02-16 2012-12-26 Wockhardt Research Centre Efflux pump inhibitors
KR20130043611A (ko) * 2010-02-25 2013-04-30 다이이찌 산쿄 가부시키가이샤 레보플록사신 또는 그의 염 또는 그들의 용매화물을 함유하는 안감염증 치료용 점안제, 안감염증의 치료 방법, 레보플록사신 또는 그의 염 또는 그들의 용매화물, 및 그의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3711343A1 (de) * 1987-04-03 1988-10-20 Bayer Ag Cephalosporinderivate, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
MA24500A1 (fr) * 1997-03-21 1998-10-01 Lg Life Sciences Ltd Derive du sel d'acide carboxylique de naphthyridine .
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis

Also Published As

Publication number Publication date
EP1458391A4 (en) 2005-05-11
PT1458391E (pt) 2007-12-10
EP1458391A1 (en) 2004-09-22
DE60222298T2 (de) 2008-01-03
WO2003045390A1 (en) 2003-06-05
EP1458391B1 (en) 2007-09-05
CA2468036C (en) 2008-01-22
US7169792B2 (en) 2007-01-30
DE60222298D1 (de) 2007-10-18
ATE372119T1 (de) 2007-09-15
ES2292844T3 (es) 2008-03-16
MXPA04005179A (es) 2004-08-11
CA2468036A1 (en) 2003-06-05
AU2002360218A1 (en) 2003-06-10
NO333196B1 (no) 2013-04-02
US20050148571A1 (en) 2005-07-07
CY1107038T1 (el) 2012-09-26
DK1458391T3 (da) 2008-01-07

Similar Documents

Publication Publication Date Title
AU6339599A (en) Quinoline derivatives and their use as antibacterial agents
PT759774E (pt) Metodo para o tratamento de infeccoes bacterianas gram-negativas por administracao de um produto de proteina bactericida indutora da permeabilidade (bip) e de um antibiotico
BR9710768A (pt) Composto composi-Æo e processos para tratamento de infec-{es bacterianas em um mamifero hospedeiro com necessidade de tal tratamento e para prepara-Æo de 6-0-metileritromicina forma i
AU2002328972A1 (en) Piperidine derivatives as antibacterial agents
WO2003088897A3 (en) Fab i inhibitors
DE60041753D1 (de) Arzneimittel zur behandlung von c. pneumoniae infektionen
AP2001002142A0 (en) 13-membered azalides and their use as antibiotic agents.
BR0002577A (pt) Suspensões orais de trovafloxacina
HUE041133T2 (hu) Dalbavancin adagolási módszer bakteriális fertõzések kezelésére
DK1434779T3 (da) Tværbundne glycopeptid-cephalosporinantibiotika
IL162689A0 (en) Methods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections
BR0309757A (pt) 6-alquilideno-penemas bicìclicos como inibidores de beta-lactamases
CY1107038T1 (el) Μεθοδος θεραπειας βακτηριακων λοιμωξεων με χρηση της γεμιφλοξασινης ή ενος αλατος αυτης και ενος αντιβιοτικου β-λακταμης
DE60131085D1 (de) Antimikrobielle sulfonamide-derivate von lipopeptidantibiotika
WO2004098500A3 (en) CARBACEPHEM ss-LACTAM ANTIBIOTICS
WO2003061704A3 (en) Combination therapy for the treatment of bacterial infections
CY1108472T1 (el) Μεθοδος για θεραπεια βακτηριακων μολυνσεων με χρηση γεμιφλοξακινης ή ενος αλατος αυτης και ενα αντιβακτηριακο παραγοντα καρβαπενεμης
AU2002334761A1 (en) Methods of treating drug-resistant bacterial infections
PL370662A1 (en) Methods of polyvalent bacteriophage preparation for the treatment of bacterial infections

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees